Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00108004
First received: April 12, 2005
Last updated: June 4, 2014
Last verified: June 2014
  Purpose

This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.


Condition Intervention Phase
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Drug: pramlintide acetate
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3B, Multicenter, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Insulin Therapy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To investigate the clinical utility and safety of pramlintide in subjects with type 1 and type 2 diabetes mellitus

Estimated Enrollment: 400
Study Start Date: April 2003
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject has a clinical diagnosis of type 1 diabetes mellitus requiring treatment with insulin for a minimum of 6 months at Screening; -OR- The subject has a clinical diagnosis of type 2 diabetes requiring treatment with insulin with or without oral antidiabetic agents for a minimum of 6 months at Screening.
  • The subject has a HbA1c of 7.0% to 11.0% at Screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00108004

  Hide Study Locations
Locations
United States, California
Research Site
Anaheim, California, United States
Research Site
Escondido, California, United States
Research Site
La Jolla, California, United States
Research Site
Los Gatos, California, United States
Research Site
San Francisco, California, United States
Research Site
Torrance, California, United States
United States, Connecticut
Research Site
New Britain, Connecticut, United States
Research Site
Norwalk, Connecticut, United States
Research Site
Norwich, Connecticut, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Clearwater, Florida, United States
Research Site
Orlando, Florida, United States
United States, Georgia
Research Site
Columbus, Georgia, United States
United States, Hawaii
Research Site
Honolulu, Hawaii, United States
United States, Idaho
Research Site
Idaho Falls, Idaho, United States
United States, Indiana
Research Site
Indianapolis, Indiana, United States
Research Site
Vincennes, Indiana, United States
United States, Kansas
Research Site
Topeka, Kansas, United States
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Lexington, Kentucky, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
United States, Michigan
Research Site
Bloomfield Hills, Michigan, United States
United States, Mississippi
Research Site
Tupelo, Mississippi, United States
United States, Nevada
Research Site
Las Vegas, Nevada, United States
Research Site
Reno, Nevada, United States
United States, New Jersey
Research Site
Moorestown, New Jersey, United States
Research Site
Neptune, New Jersey, United States
Research Site
Roseland, New Jersey, United States
United States, New York
Research Site
New York, New York, United States
Research Site
Williston Park, New York, United States
Research Site
Yonkers, New York, United States
United States, North Carolina
Research Site
Greenville, North Carolina, United States
United States, Ohio
Research Site
Lakewood, Ohio, United States
Research Site
Westlake, Ohio, United States
United States, Oregon
Research Site
Portland, Oregon, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Wilkes Barre, Pennsylvania, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
Research Site
Sumter, South Carolina, United States
United States, Tennessee
Research Site
Chattanooga, Tennessee, United States
Research Site
Knoxville, Tennessee, United States
Research Site
Memphis, Tennessee, United States
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Arlington, Texas, United States
Research Site
Dallas, Texas, United States
United States, Washington
Research Site
Olympia, Washington, United States
United States, Wisconsin
Research Site
Madison, Wisconsin, United States
Research Site
Milwaukee, Wisconsin, United States
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00108004     History of Changes
Other Study ID Numbers: 137-155
Study First Received: April 12, 2005
Last Updated: June 4, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Diabetes
Amylin
Symlin
pramlintide acetate

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Islet Amyloid Polypeptide
Pramlintide
Anti-Obesity Agents
Appetite Depressants
Central Nervous System Agents
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014